Pfizer (NYSE:PFE) Shares Up 1.5% - What's Next?

Key Points

• Shares rose 1.5% to $25.90 on Wednesday amid lighter-than-average volume, while analysts have an average target of $27.88 and a consensus rating of "Hold."
• Pfizer struck a licensing agreement with Novavax for the Matrix‑M adjuvant to expand its vaccine toolbox, while simultaneously exiting its 11.7% stake in ViiV Healthcare as it reshapes its portfolio.
• The company declared a quarterly dividend of $0.43 (annualized $1.72), implying a 6.6% yield and a payout ratio of 100%.

Pfizer Inc. (NYSE:PFE - Get Free Report)'s share price rose 1.5% during trading on Wednesday . The stock traded as high as $25.92 and last traded at $25.90. Approximately 45,547,914 shares were traded during trading, a decline of 7% from the average daily volume of 48,881,133 shares. The stock had previously closed at $25.52.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst/media endorsement: The Motley Fool lists Pfizer as one of three "no‑brainer" dividend stocks to buy, highlighting income investors' interest in PFE's yield and shareholder return prospects. 3 No-Brainer Dividend Stocks to Buy Right Now -- Including Pfizer
• Positive Sentiment: Strategic deal flow: Pfizer struck a licensing arrangement with Novavax around the Matrix‑M adjuvant to support vaccine development — a deal that can broaden Pfizer's vaccine toolbox and pipeline optionality even if it includes payments to Novavax. Markets often view productive R&D partnerships as constructive for future growth. Novavax enters license agreement with Pfizer for vaccine development
• Neutral Sentiment: Management commentary: CEO Albert Bourla discussed drug pricing trends and AI in healthcare on 'Money Movers' — useful directional color on strategy but not an immediate earnings change. Investors will watch for policy specifics and margin impact. Pfizer CEO Albert Bourla: U.S. drug prices are coming down
• Neutral Sentiment: Industry outlook: Takeaways from the JPMorgan Healthcare Conference (coverage by CNBC) emphasize drug‑pricing pressure, patent cliffs and dealmaking across pharma — themes that shape long‑term investor expectations but are already baked into many valuations. Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
• Neutral Sentiment: Valuation check: Commentary assessing Pfizer's valuation as investors reassess recent shareholder returns underscores that PFE is viewed as a value/dividend play by some, while others point to competitive and pricing risks. Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns
• Negative Sentiment: Asset reallocation: Pfizer is exiting its 11.7% stake in HIV specialist ViiV Healthcare as Shionogi increases its holding — a move that reduces Pfizer's direct exposure to that JV's upside and signals portfolio reshaping that may remove a future revenue stream. Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits
• Negative Sentiment: Competitive pressure: Analyst comparisons (Zacks) highlight Eli Lilly's accelerating growth from GLP‑1 drugs as a competitive headwind across large-cap pharma; sustained outperformance by peers can weigh on Pfizer's relative multiple. Which Pharma Stock Stands Taller Right Now: LLY or PFE?

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Scotiabank began coverage on shares of Pfizer in a research report on Thursday, November 13th. They issued a "sector outperform" rating and a $30.00 price target for the company. Sanford C. Bernstein reissued a "market perform" rating and issued a $30.00 price objective on shares of Pfizer in a research note on Friday, October 31st. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Wednesday, December 17th. Citigroup initiated coverage on Pfizer in a research note on Tuesday, December 2nd. They issued a "neutral" rating and a $26.00 price objective for the company. Finally, HSBC reissued a "buy" rating and set a $29.00 target price on shares of Pfizer in a research note on Wednesday, December 10th. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and an average target price of $27.88.

Pfizer Trading Up 1.5%

The company's 50 day moving average price is $25.38 and its 200 day moving average price is $24.99. The firm has a market cap of $147.26 billion, a PE ratio of 15.06 and a beta of 0.47. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts' consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion for the quarter, compared to the consensus estimate of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.6%. Pfizer's payout ratio is currently 100.00%.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Norges Bank acquired a new position in Pfizer during the second quarter worth approximately $2,270,157,000. Vanguard Group Inc. boosted its stake in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company's stock valued at $12,928,730,000 after purchasing an additional 10,198,330 shares during the period. Franklin Resources Inc. grew its stake in shares of Pfizer by 47.8% during the third quarter. Franklin Resources Inc. now owns 25,070,148 shares of the biopharmaceutical company's stock valued at $638,787,000 after acquiring an additional 8,108,887 shares in the last quarter. Neuberger Berman Group LLC increased its holdings in Pfizer by 203.8% during the 3rd quarter. Neuberger Berman Group LLC now owns 9,012,811 shares of the biopharmaceutical company's stock worth $229,346,000 after purchasing an additional 6,045,763 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its holdings in Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company's stock valued at $468,174,000 after acquiring an additional 5,978,927 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.